Judy DiClemente | IR |
Nikhil Lalwani | President, CEO & Director |
Stephen Carey | CFO, SVP, Finance & Corporate Secretary |
Elliot Wilbur | Raymond James & Associates |
Vamil Divan | Guggenheim Securities |
Gregory Fraser | Truist Securities |
Brandon Folkes | Cantor Fitzgerald |
Oren Livnat | H.C. Wainwright & Co. |
Good morning, everyone, and my name is Ashley, and I'll be your conference operator. At this time, I'd like to welcome everyone to ANI Pharmaceuticals' Fourth Quarter and Full Year 2022 financial results. [Operator Instructions].
As a reminder, this conference call is being recorded today, March 9, 2023. It is now my pleasure to turn the floor over to Ms.